Study #2023-0163
A phase Ib trial of Eribulin in combination with Irinotecan and Temozolamide in children with relapsed or refractory solid tumors
MD Anderson Study Status
Enrolling
Treatment Agent
Eribulin, Irinotecan, Temozolomide
Description
To find the recommended dose of eribulin that can be given in combination with irinotecan and temozolomide to treat relapsed and/or refractory solid tumors.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Refractory Solid Tumors
Study phase:
Physician name:
Fiorela Hernandez Tejada
Department:
Pediatrics
For general questions about clinical trials:
1-877-632-6789
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.